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doi:10.1016/j.ejvs.2008.06.021Abstract Diagnosis of carotid body tumor (CBT) was made in a 36 years old woman. The pre-
operative examination included genetic analysis of the succinate dehydrogenase that showed
a mutation in his subunit D responsible of multiple paraganglioma at slow growth. Subsequently
a thoraco-abdominal CT and indium111 octreotide body scan were performed and another para-
ganglioma was detected in the anterior mediastinum. CBT was surgically removed; differently
the thoracic lesion due to his benign genetic profile was not treated. During a 3-years follow-up
the thoracic paraganglioma as expected, didn’t increase. Genetic analysis of succinate dehy-
drogenase, should be performed in the management of CBT.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Carotid body tumours (CBT) can cause significant disability
and death. The succinate dehydrogenase (SDH) genes
encode three subunits (B,C,D) of mitochondrial complex II,
a heterotetrameric complex involved in the Krebs cycle and
the aerobic electron-transport chain. Mutations of SDH are
implicated in familial and sporadic form of CBT.1 Transmis-
sion is autosomal dominant with incomplete penetrance.212638; fax: þ39 498212637.
.1@unipd.it (M. Antonello).
ty for Vascular Surgery. PublisheWhen related to one of these mutations, CBT is frequently
associated with other silent paraganglioma (PGL).1
Report
A 36 year old female was referred with a right CBT. At age
16 a jugulotympanic PGL had been resected. Five years
later a local recurrence was treated in another institution
which required ligation of the left internal carotid artery.
The operation was complicated by cranial nerve palsies. For
the present admission, the patient presented with a right-
sided neck mass, left tongue deviation, motor impairment
of the scalene muscle block and paralysis of the IX, X, XId by Elsevier Ltd. All rights reserved.
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raphy of the neck showed a mass of 3.5 by 3 cms splaying
the carotid artery bifurcation (Fig. 1). Normal levels of
plasma and urinary metanephrine and chromogranin-A
were found.
Single nucleotide polymorphism of SDH was assessed
using a Big-Dye Terminators v.3.1 Cycle Sequencing Kit and
ABI Prism 3100 DNA Analyzer (Applied Biosystems). These
studies demonstrated a mutation (c.341G>C p.Y114C) of
the sub-unit D gene. This polymorphism has been associ-
ated with a high risk of multiple PGL.2 A thoraco-abdominal
CT angiogram was performed and demonstrated a mass of
3.5 by 2 cm in the anterior mediastinum, suggestive of
PGL (Fig. 2A). An indium111 octreotide body scan confirmed
the diagnosis.
After a multidisciplinary discussion involving an endocri-
nologist, thoracic and vascular surgeons it was decided,
because of the age of the patient and the benign nature of
PGLs, to defer the treatment of the thoracic lesion and to
follow it with annual MR scans. Because of the natural
history of Shamblin Type II CBT (surrounding carotid vessels
or partly enclosing them) and the likelihood of future
symptoms related to local compression, the CBT was
resected. The patient’s postoperative course was unre-
markable and she was discharged on postoperative day 4.
The patient was followed-up with annual carotid duplex
scan and thoracic MR that showed no signs of local
recurrence or enlargement of the thoracic PGL at 3-years
(Fig. 2B).
Discussion
Mutation of the sub-unit D of the SDH gene is found in 79%
of head and neck paraganglioma (HNP), in 53% of adrenal
pheochromocytoma, in 39% of extra-adrenal pheochromo-
cytoma and in 78% of multifocal benign tumors.2 Therefore,Figure 1 Preoperative angio-MR showing the carotid body
tumor on the right carotid bifurcation.
Figure 2 (a) Preoperative angio-CT showing a paraganglioma
in the anterior mediastinum; (b) Angio-MR performed after 3
years of follow-up showing the unchanged size of the paragan-
glioma in the anterior mediastinum.all patients with this mutation should undergo other studies
such as contrast enhanced thoracoabdominal CT scan and
Indium111 octreotide body scan to evaluate other possible
PGL sites.
Management of these lesions should be based on their
malignant potential and on their likelihood of causing
symptoms by local growth and compression of adjacent
structures. For most CBTs early surgical excision represents
the treatment of choice to minimize risks of cranial nerve
and carotid artery involvement or injury. When CBT is
classified as Shamblin type I or II surgical excision is strongly
recommended.
To treat the thoracic PGL a traditional surgical approach
is the only method to obtain a radical resection of the mass
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50% when resection is performed with other minimally
invasive techniques. The surgical procedure itself has an
operative mortality of about 6%.3 In the case reported the
multidisciplinary team decided, considering the young age
of the patient, the operative risk and the benign character
of PGL suggested by the genetic analysis, to treat the
thoracic PGL conservatively. As predicted by its genetic
profile the mediastinal PGL did not enlarge during the three
year follow-up.
Molecular screening for mutations in genes coding for
the subunit B, C and D of SDH, is recommended in cases of
familial and sporadic HNP to guide a multidisciplinary team
in the diagnosis and management of the lesions. In sporadicHNP with a SDH mutation screening should also be
performed on the family.References
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